ClinicalTrials.gov
ClinicalTrials.gov Menu

Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01428739
Recruitment Status : Completed
First Posted : September 5, 2011
Last Update Posted : January 25, 2017
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Brief Summary:
Correlation between MRS and Tumor Response Therapy in Breast Cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: MRS Not Applicable

Detailed Description:
Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer
Study Start Date : December 2007
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources


Intervention Details:
    Device: MRS
    Procedure
    Other Name: Philips 3 Tesla MRI Scanner


Primary Outcome Measures :
  1. MRS Correlation with Treatment Response [ Time Frame: Up to One Year ]
    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment


Secondary Outcome Measures :
  1. Correlation with Tumor Stage [ Time Frame: Up to One year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01428739


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT01428739     History of Changes
Other Study ID Numbers: 23701
First Posted: September 5, 2011    Key Record Dates
Last Update Posted: January 25, 2017
Last Verified: October 2014

Keywords provided by AHS Cancer Control Alberta:
cancer
MRS
Treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases